Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

NCT00770848 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00770848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00770848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2008
Completion date
April 30, 2012
Enrollment
162 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, castrate-resistant prostate cancer, mestastatic prostate cancer, prostate cancer